跳至主要内容
临床试验/NCT05914987
NCT05914987招募中不适用

Profile-Related Evidence Determining Individualized Cancer Therapy in Pancreatic Cancer (PREDICT-PANC)

Medical College of Wisconsin2 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2023年12月4日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
1,000
试验地点
2
主要终点
Number of Subjects Receiving Targeted Therapy

研究概览

简要总结

This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years.
  • Pathologically confirmed pancreatic cancer.
  • Ability to understand a written informed consent document and the willingness to sign it

排除标准

  • Age <18 years.
  • Primary cancer diagnosis other than pancreatic cancer.

结局指标

主要结局

Number of Subjects Receiving Targeted Therapy

时间窗: 5 years

This measure is the number of study subject's whose treating physician prescribes and subsequently receives the therapeutic recommendation of the Molecular Tumor Board.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mandana Kamgar, MD

Assistant Professor

Medical College of Wisconsin

研究点 (2)

Loading locations...

相似试验

Determining Individualized Cancer Therapy in... | 临床试验